Method of treating malignant mesothelioma
AssigneeThe University of Tokyo
InventorsChikao Morimoto, Kei Ohnuma, Teruo Inamoto
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapeutic agent for malignant mesothelioma comprising a substance which inhibits binding of CD26 to extracellular matrix such as an siRNA targeting CD26 cDNA or an anti-CD26 antibody. The present invention also relates to a method of treating malignant mesothelioma, which comprises administering the substance to a patient in need thereof.
Claims12
A method for the treatment of malignant mesothelioma, comprising a step of administering an effective amount of an anti-CD26 humanized antibody comprising a variable region of 14D10 to a subject in need thereof.
A method for inhibiting growth of a malignant mesothelioma cell, which comprises contacting a malignant mesothelioma cell with an anti-CD26 humanized antibody comprising a variable region of 14D10.
A method for inhibiting growth of a malignant mesothelioma cell, which comprises contacting the malignant mesothelioma cell and an effector cell with an anti-CD26 humanized antibody comprising a variable region of 14D10, wherein the effector cell is a cell specific to the antibody.
A method for lysing a malignant mesothelioma cell, which comprises contacting the malignant mesothelioma cell and an effector cell with an anti-CD26 humanized antibody comprising a variable region of 14D10, wherein lysis of the cell is caused by antibody-dependent cell-mediated cytotoxicity and wherein the effector cell is a cell specific to the antibody.
A method for lysing a malignant mesothelioma cell, which comprises contacting the malignant mesothelioma cell and an effector cell with an anti-CD26 humanized antibody comprising a variable region of 14D10, wherein the effector cell is a cell specific to the antibody.
Dependencies are inferred from the claim text.